Cargando…

Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms

The Janus kinase 2 (JAK2)-driven myeloproliferative neoplasms (MPNs) are associated with clonal myelopoiesis, elevated risk of death due to thrombotic complications, and transformation to acute myeloid leukemia (AML). JAK2 inhibitors improve the quality of life for MPN patients, but these approved t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Vasundhara, Wright, Kenneth L., Epling-Burnette, Pearlie K., Reuther, Gary W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734315/ https://www.ncbi.nlm.nih.gov/pubmed/33329600 http://dx.doi.org/10.3389/fimmu.2020.604142

Ejemplares similares

Immune dysregulation in myelodysplastic syndrome
por: Sugimori, Chiharu, et al.
Publicado: (2010)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes
por: Mailloux, Adam W., et al.
Publicado: (2013)

Bone marrow niche dysregulation in myeloproliferative neoplasms
por: Curto-Garcia, Natalia, et al.
Publicado: (2020)

Role of Polyamines in Immune Cell Functions
por: Hesterberg, Rebecca S., et al.
Publicado: (2018)

Hypothetical Atopic Dermatitis-Myeloproliferative Neoplasm Syndrome
por: Kawakami, Toshiaki, et al.
Publicado: (2015)

Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms
por: Marin Oyarzún, Cecilia P., et al.
Publicado: (2019)

Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms
por: Fisher, Daniel Arthur Corpuz, et al.
Publicado: (2021)

Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives
por: Vannucchi, Alessandro M, et al.
Publicado: (2009)

The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2018)

Dysregulation of the intrinsic apoptotic pathway mediates megakaryocytic hyperplasia in myeloproliferative neoplasms
por: Malherbe, Jacques A J, et al.
Publicado: (2016)

Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation
por: Bennemann, Karla, et al.
Publicado: (2012)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

MDS shows a higher expression of hTERT and alternative splice variants in unactivated T-cells
por: Dong, Wen, et al.
Publicado: (2016)

Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies
por: Mascarenhas, John, et al.
Publicado: (2011)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

The microenvironment in myeloproliferative neoplasm
por: Méndez-Ferrer, Simón, et al.
Publicado: (2018)

Spleen in myeloproliferative neoplasms
por: Barosi, Giovanni
Publicado: (2018)

Targeted therapies for myeloproliferative neoplasms
por: Li, Bing, et al.
Publicado: (2019)

Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression
por: Carnaz Simões, Ana Micaela, et al.
Publicado: (2022)

Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression
por: Simões, Ana Micaela Carnaz, et al.
Publicado: (2022)

Deactylase inhibition in myeloproliferative neoplasms
por: Mithraprabhu, Sridurga, et al.
Publicado: (2010)

Guidelines for the management of myeloproliferative neoplasms
por: Choi, Chul Won, et al.
Publicado: (2015)

The Hematopoietic Niche in Myeloproliferative Neoplasms
por: Schmitt-Graeff, Annette H., et al.
Publicado: (2015)

Calreticulin Mutations in Myeloproliferative Neoplasms
por: Lavi, Noa
Publicado: (2014)

Apoptosis deregulation in myeloproliferative neoplasms
por: Tognon, Raquel, et al.
Publicado: (2013)

Mutant Calreticulin in the Myeloproliferative Neoplasms
por: Prins, Daniel, et al.
Publicado: (2020)

Experimental Modeling of Myeloproliferative Neoplasms
por: Lanikova, Lucie, et al.
Publicado: (2019)

Novel therapeutics in myeloproliferative neoplasms
por: Venugopal, Sangeetha, et al.
Publicado: (2020)

Molecular pathogenesis of the myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2021)

Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
por: Person, Fermin, et al.
Publicado: (2021)

The Pathogenic Role of Dysregulated Epigenetic Modifications in Autoimmune Diseases
por: Wu, Haijing, et al.
Publicado: (2019)

Mesenchymal Cell Reprogramming in Experimental MPL(W515L) Mouse Model of Myelofibrosis
por: Han, Ying, et al.
Publicado: (2017)

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial
por: Grauslund, Jacob Handlos, et al.
Publicado: (2023)

Paving the way to improve therapy for Myeloproliferative Neoplasms
por: Bywater, Megan, et al.
Publicado: (2022)

Philadelphia-negative chronic myeloproliferative neoplasms
por: Bittencourt, Rosane Isabel, et al.
Publicado: (2012)

CALR mutation characterization in myeloproliferative neoplasms
por: Bilbao-Sieyro, Cristina, et al.
Publicado: (2016)

Genetic–pathologic characterization of myeloproliferative neoplasms
por: Kim, Yonggoo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4tvrmschtf7nk96s94eslqccs3